Skip to main content
Premium Trial:

Request an Annual Quote

NCI, Waters, Agilent, PerkinElmer, Beckman Coulter, Qiagen, ActiveSight, LifeSpan, MBL, TB Alliance, BG Medicine, Avac, CytoStore, Bruker, DSMZ, GenoLogics, SGUL


NCI to Hold Public Discussion of Its Clinical Proteomic Technology Initiative

The National Cancer Institute will hold a public discussion of its Clinical Proteomic Technology Initiative and its requests for applications for the new program on Feb. 27 from 10 a.m. to 3 p.m. EST. The meeting will describe the initiative and answer questions from potential applicants.

The meeting will be held at the National Institutes of Health's William H. Natcher Conference Center at 45 Center Drive in Bethesda, Md. The meeting can be viewed via webcast at To register for the event, visit

Waters to Pay Agilent $6.1M to Settle HPLC Patent-Infringement Suit in UK

Waters will pay Agilent a one-time payment of £3.5 million ($6.1 million) as part of a settlement agreement to resolve a patent-infringement suit involving high performance liquid chromatography technology.

In 2002, Waters stopped using a portion of the pump technology used in its Alliance HPLC instruments as a result of a patent infringement suit that was brought before a court in the United Kingdom.

As a result of the settlement, Waters has revised downward its fourth-quarter 2005 and full-year 2005 earnings results that were previously reported on Jan. 24 to include a pre-tax $3.1 million for provision of damages and estimated remaining costs related to the suit.

The revision results in a reduction of earnings per diluted share for the fourth quarter to $0.69 from $0.71. For the full year 2005, the revision results in a reduction of earnings per diluted share to $1.74 from $1.76.

Other patent infringement suits between Waters and Agilent, similar to the one in the UK, are pending in France and Germany. Waters said it believes that damages from those suits are "unlikely to be materially different from amounts previously recorded."

Expanding in China, PerkinElmer Opens New Tech Center in Shanghai; Will Be New China HQ

PerkinElmer this week said it has opened a new technology center in Shanghai, China, and that it will consolidate into it three existing facilities in that city.

The new center, which PerkinElmer said "allows for easy expansion," aims to bring together PerkinElmer's sales, service, customer care, and technology-support functions, and will be the company's regional headquarters for greater China.

The new center is located at Zhangjiang Bio-Pharma Park in Pudong New Territory.

In 2003, PerkinElmer opened a subsidiary to provide sales and service for its life and analytical sciences products. That space, which is located in the Shanghai WaiGaoQiao Free Trade Zone, was to employ approximately 100 sales and service staffers, the company said at the time.

It was not immediately clear if this space is one of the three the company plans to consolidate into the new technology center.

Beckman Coulter's Q4 Revenues Fall 5.4 Percent as Income Drops 70 Percent

Beckman Coulter reported last week that its fourth-quarter sales fell by 5.4 percent to $655.5 million from $693 million during the year-ago period.

Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth.

Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.

Beckman reaffirmed its outlook for 2006 that was stated on Nov. 2, 2005, when the company released its third-quarter earnings report. Assuming stable currency, sales should be in the range of $2.53 billion to $2.60 billion, the company said.

For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.

Beckman CEO Scott Garrett said he expects growth in 2006 to be led by placements of the company's DxC 600 and 800 Autochemistry platforms, and of the UniCel DxI 800 immunoassay systems.

Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.

As of Dec. 31, 2005, Beckman had $57.6 million in cash and cash equivalents.

Qiagen to Bundle Reagents With ActiveSight's CrystalScan for Protein-crystallization Offering

Qiagen will bundle its sample preparation consumables with ActiveSight's CrystalScan protein-crystallization screening service, the companies said this week.

Financial terms of the agreement were not disclosed.

LifeSpan Sells GPCR Portfolio to MBL, Plans to Continue Antibody Line

LifeSpan BioSciences has sold "most of its existing catalog" of antibodies to Medical and Biological Laboratories International, LifeSpan confirmed this week.

The Massachusetts-based subsidiary of Nagoya, Japan-based MBL bought 921 antibodies to about 400 different protein targets, including 800 GPCR antibodies.

"MBL has a broader reach in terms of selling this product," LifeSpan CEO Joseph Brown said.

Brown said LifeSpan plans to continue developing antibodies to gene-target proteins and will consider future distribution deals with MBL.

Financial details of the deal were not available.

TB Alliance and BG Medicine to Collaborate on Tuberculosis Biomarker Discovery

The Global Alliance for TB Drug Development and BG Medicine announced this week a collaborative deal to identify biomarkers for tuberculosis drug development.

The collaboration will last six months, the partners said.

Under the deal, BG Medicine will use its proteomic and metabolomic analytical platforms to analyze samples provided by Colorado State University. TB Alliance will fund the project, with help from a grant from the Netherlands Ministry of Foreign Affairs.

Financial details were not provided.

TB Alliance is a non-profit, public-private partnership supported by the Bill and Melinda Gates Foundation and the Rockefeller Foundation.

Avac Awards CytoStore $324K for Organelle-Purification Kits

CytoStore will develop and market a new line of organelle-purification kits with the support of a $323,750 investment from Avac, a non-profit Canadian agrivalue investor, CytoStore said last week.

The kits will use "agriculturally derived oilbody technology" developed and licensed by CytoStore from SemBioSys, said CytoStore CEO Casey Eitner in a statement.

The kits will be designed to complement CytoStore's existing DualTrap and TripleExpress products for measuring myeloperoxide activity and protein expression.

CytoStore is a spin-off from University Technologies of the University of Calgary.

Bruker and DSMZ to Identify, Type Microorganisms Using Mass Spec

Bruker Daltonik and the German Collection of Microorganisms and Cell Cultures (DSMZ) will together identify and classify microorganisms from MALDI-TOF peptide and protein profiles, Bruker and DSMZ said this week.

The DSMZ will use Bruker's CLINPROT BioTyper system to generate protein profiles and analyze data.

As part of the collaboration, Bruker and DSMZ will generate a database including microorganism species and strains in application areas such as microbiological classification; clinical and diagnostic infectious disease research; and environmental analysis, food safety, and water quality.

Financial terms were not disclosed.

GenoLogics to Provide SGUL Medical Biomics Center with Data Management System

GenoLogics Life Sciences Software said this week that it has signed a deal to provide its ProteusLIMS laboratory and scientific data management system to the St. George's University of London Medical Biomics Center.

Specific terms of the arrangement were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.